News
Bristol Myers Squibb & Co (NYSE:BMY) reported second-quarter 2025 revenues of $12.27 billion, beating the consensus of $11.31 ...
The firm is leveraging its expertise in the immuno-oncology space to expedite development of newer agents like the bispecific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback